The testosterone replacement therapy for prostate cancer patients: Time to take the leap?

Hypogonadism is highly prevalent among prostate cancer patients due to treatment-induced androgen deprivation.

• New systemic therapies have resulted in significant decreases in prostate cancer death but at the cost of increased long-term treatment-induced hypogonadism.
• Androgen deprivation therapy (ADT) is a primary cause of hypogonadism in this population.
• The proportion of men living with long-term treatment-induced hypogonadism has increased as survivorship improves.

TRT has demonstrated benefits in men without prostate cancer history, including improved erectile function, reduced cardiovascular morbidity, and improved overall survival.

• In the general male population, TRT proved ability to improve erectile function.
• TRT reduced cardiovascular morbidity in men without prostate cancer history.
• These benefits translated into improved overall survival in the non-PCa population.
• These established benefits form the rationale for investigating TRT in prostate cancer survivors.

The safety of TRT in prostate cancer patients remains an open and unresolved question.

• Whether TRT is safe and efficient in PCa patients is described as 'an open question.'
• The paper presents an overview on the safety of TRT for PCa patients.
• Optimal population eligible for TRT after PCa treatment has not been definitively established.
• The review discusses which patient populations might be appropriate candidates for TRT post-treatment.

The paper identifies the need to define the optimal population eligible for TRT following prostate cancer treatment.

• The discussion focuses on identifying which PCa patients might safely receive TRT.
• Factors such as disease stage, treatment type, and oncologic risk are relevant to eligibility.
• The title's rhetorical question 'Time to take the leap?' suggests the field is at a decision point regarding TRT adoption.
• The authors discuss criteria that could guide patient selection for TRT after PCa treatment.

Prospective randomized evidence regarding TRT safety and efficacy in prostate cancer patients remains limited.

• The review format suggests reliance on observational and limited prospective data rather than robust randomized controlled trials.
• The framing of TRT safety as 'an open question' implies absence of definitive high-level evidence.
• The provocative title implies the field has not yet reached consensus on TRT use in PCa patients.
• The paper calls implicitly for better evidence to guide clinical decision-making in this population.